Aequus Pharmaceuticals Inc.

OTCPK:AQSZ.F Stock Report

Market Cap: US$462.1k

Aequus Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Doug Janzen

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure11.9yrs
CEO ownership9.5%
Management average tenureno data
Board average tenure6.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Doug Janzen's remuneration changed compared to Aequus Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-CA$3m

Jun 30 2024n/an/a

-CA$3m

Mar 31 2024n/an/a

-CA$3m

Dec 31 2023n/an/a

-CA$3m

Sep 30 2023n/an/a

-CA$3m

Jun 30 2023n/an/a

-CA$3m

Mar 31 2023n/an/a

-CA$3m

Dec 31 2022CA$206kCA$206k

-CA$3m

Sep 30 2022n/an/a

-CA$3m

Jun 30 2022n/an/a

-CA$2m

Mar 31 2022n/an/a

-CA$2m

Dec 31 2021CA$225kCA$225k

-CA$2m

Sep 30 2021n/an/a

-CA$2m

Jun 30 2021n/an/a

-CA$2m

Mar 31 2021n/an/a

-CA$1m

Dec 31 2020CA$212kCA$212k

-CA$1m

Sep 30 2020n/an/a

-CA$2m

Jun 30 2020n/an/a

-CA$2m

Mar 31 2020n/an/a

-CA$3m

Dec 31 2019CA$191kCA$191k

-CA$3m

Sep 30 2019n/an/a

-CA$3m

Jun 30 2019n/an/a

-CA$3m

Mar 31 2019n/an/a

-CA$3m

Dec 31 2018CA$180kCA$180k

-CA$3m

Sep 30 2018n/an/a

-CA$3m

Jun 30 2018n/an/a

-CA$3m

Mar 31 2018n/an/a

-CA$4m

Dec 31 2017CA$258kCA$210k

-CA$4m

Compensation vs Market: Insufficient data to establish whether Doug's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Doug's compensation has been consistent with company performance over the past year.


CEO

Doug Janzen (55 yo)

11.9yrs

Tenure

Mr. Douglas Glen Janzen, also known as Doug, is Director of Elevate Farms Inc. from September 2022. Mr. Janzen has experience in banking investments and managing growth companies with a particular focus on...


Board Members

NamePositionTenureCompensationOwnership
Douglas Janzen
Chairman11.9yrsno data9.46%
$ 43.7k
Marc Lustig
Independent Director3.8yrsCA$3.72k5.21%
$ 24.1k
Christopher Clark
Director10yrsCA$3.72kno data
Iqbal Ahmed
Chairman of Strategic Advisory Board6.1yrsno datano data
Anne Stevens
Director10yrsCA$3.72kno data
Rosa Braga-Mele
Member of Strategic Advisory Board6.1yrsno datano data
Vikram Lekhi
Member of Strategic Advisory Board6.1yrsno datano data
Ken Patterson
Member of Strategic Advisory Board6.1yrsno datano data

6.1yrs

Average Tenure

51yo

Average Age

Experienced Board: AQSZ.F's board of directors are considered experienced (6.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 10:26
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aequus Pharmaceuticals Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nathan CaliNOBLE Capital Markets, Inc.